Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study
Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study
Blog Article
Background and Objectives: A recent clinical trial has demonstrated that breast cancer with low-HER2 expression levels responds to trastuzumab deruxtecan treatment.This has prompted a re-evaluation of HER2-targeted therapies in the HER2-negative group.Further research is required in the form of more detailed information about HER2-negative breast cancers with HER2-null, HER2-ultralow, and HER2-low subgroups.This study represents a novel approach to this field.
Materials and Methods: HER2-negative breast cancer patients were classified into three groups as HER2-null, HER2-ultralow, and HER2-low.A comparison of clinicopathological features was analyzed retrospectively.Results: Of 722 patients, 22.3% ludwig modular hardware were HER2-null, 23.
7% were HER2-ultralow, 54.0% were HER2-low.While two-thirds of all the patients were evaluated as having T2 tumors, T4 tumors constituted 2.4%.
Among HER2-negative cases, 11.8% were triple-negative and 88.2% were hormone-positive.The mean tumor diameter was 0.
57 cm larger in the HER2-ultralow group than in the HER2-null group and 0.34 cm larger in the HER2-low group than in the HER2-null group.HER2-null tumors tend to be smaller.The HER2-low group was more likely to relapse than the HER2-null group.
There were no significant differences in the distribution of hormone positivity or negativity (TNBC) among the groups; they accounted for 89.2% and 10.8% of all cases, respectively.Conclusions: HER2-negative breast cancer is a heterogeneous disease and deserves a detailed the official playboy bunny gold rabbit head zippo lighter review in terms of diagnosis and treatment.
HER2-ultralow tumors are larger in size and have a prognosis comparable to HER2-null tumors.HER2-low tumors tend to recur much more frequently and with poorer outcomes.In this field, new therapeutic approaches may result in better outcomes.